Nachrichten zur Abbvie Inc. Aktie

ABBVs Newly Added Parkinsons Disease Drug Meets Second Study Goal

Data from a late-stage study shows that AbbVies tavapadon reduced the burden of Parkinsons disease. The drug previously demonstrated efficacy…

AbbVies Parkinsons Disease drug meets main goal in late-stage trial By Reuters

AbbVies Parkinsons Disease drug meets main goal in late-stage trial…

IRW-News: ACCESSWIRE News Network : Ripple Therapeutics kündigt Kooperations- und Lizenzoptionsvereinbarung mit AbbVie zur Entwicklung von innovativen Therapien für das Glaukom-Management an

IRW-PRESS: ACCESSWIRE News Network : Ripple Therapeutics kündigt Kooperations- und Lizenzoptionsvereinbarung mit AbbVie zur Entwicklung von innovativen Therapien für das…

US Rheumatologists Believe Biogen’s Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data

Despite favorable views on litifilimab, AbbVie’s Rinvoq and BMS’ Sotyktu capture the most prescriber interest for approval, according to Spherix…

The Zacks Analyst Blog Highlights Visa, AbbVie, Anheuser-Busch, Servotronics and United-Guardian

Visa, AbbVie, Anheuser-Busch, Servotronics and United-Guardian are included in this Analyst Blog.…

Top Stock Reports for Visa, AbbVie & Anheuser-Busch

Todays Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and Anheuser-Busch…

Global Hematologic Malignancies Market Size To Worth USD 144.58 Billion By 2033 | CAGR Of 7.97%

The Global Hematologic Malignancies Market Size was Valued at USD 67.18 Billion in 2023 and the Worldwide Hematologic Malignancies Market…

Global Diabetes Associated Ophthalmic Treatment Market Size To Exceed USD 56.43 Billion By 2033 l CAGR Of 6.61%

The Global Diabetes Associated Ophthalmic Treatment Market Size was Valued at USD 29.75 Billion in 2023 and the Worldwide Diabetes…

AbbVie Already Has The Next Humira

…

Breaking News: NurExone Biologic & AbbVie & Faktor 10.000 & der Nobelpreisträger

Anzeige / WerbungDr. Lior Shatiel, CEO von NurExone Biologic, vergleicht auf der bevorstehenden "Bioprocess International Conference" in Boston die Ansätze…

AbbVie: Vorsicht vor überhitztem Kurs! Aktienanalyse

Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), stuft die…

AbbVie’s SKYRIZI[®] (risankizumab) Is Recommended by NICE as an Option for Use in Adults with Moderately to Severely Active Ulcerative Colitis

For UK consumer, medical and trade media only · In final guidance published today, adults in England and Wales…

AbbVie (ABBV) Gets Nod in EU for Lymphoma Drugs Expanded Use

AbbVies (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as…

S&P 500, Nasdaq, Dow hold onto gains, Advanced Micro Devices acquires ZT Systems: Yahoo Finance

The major indexes (^DJI,^GSPC, ^IXIC) are holding onto last week’s gains ahead of Federal Reserve Chair Jerome Powell’s remarks at…

The Zacks Analyst Blog Highlights Alphabet, AbbVie, Qualcomm and Flanigans

Alphabet, AbbVie, Qualcomm and Flanigans are part of the Zacks top Analyst Blog.…

Analyst revises AbbVie stock price target on drug-sale estimates

This is what could happen next to AbbVie shares.…

Top Research Reports for Alphabet, AbbVie & QUALCOMM

Todays Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), AbbVie Inc. (ABBV) and QUALCOMM…

3 Big Drug Stocks to Watch on Raised 2024 Earnings & Sales View

Here we discuss three drugmakers, Eli Lilly and Company (LLY), Pfizer (PFE) and AbbVie (ABBV), following their increase in sales…

Warren Buffetts Approach To Investing In Election Years - Apple (NASDAQ:AAPL), AbbVie (NYSE:ABBV)

Warren Buffett, known as the Oracle of Omaha, is a highly successful American investor who manages his portfolio consistently, regardless…

Should You Buy AbbVie (ABBV) After Q2 Beat, Guidance Raise?

Investors who own AbbVies (ABBV) stock may stay invested as the company has faced its biggest challenge, Humiras patent cliff,…

Global Regenerative Medicine Market Size To Worth USD 349.93 Billion By 2033 | CAGR of 27.06%

The Global Regenerative Medicine Market Size was Valued at USD 31.90 Billion in 2023 and the Worldwide Regenerative Medicine Market…

U.S. Menopause Market Trends Analysis Report 2024-2030 Featuring Pfizer, Novo Nordisk, TherapeuticsMD, Bayer, AbbVie, Pure Encapsulations, and PADAGIS

Dublin, July 29, 2024 (GLOBE NEWSWIRE) -- The "U.S. Menopause Market Size, Share & Trends Analysis Report by…

AbbVie: Q2 Earnings Validate Bullish Case

…

Analyst Report: AbbVie Inc

…

Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRKs Positive Pipeline News

AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizers (PFE) phase III studies achieve primary…

AbbVie (ABBV) Q2 2024 Earnings Call Transcript

ABBV earnings call for the period ending June 30, 2024.…

AbbVie: Humira bald nicht mehr Nummer Eins? Aktienanalyse

Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt in…

AbbVie hikes full-year earnings guidance as Humira sales top estimates By Investing.com

AbbVie hikes full-year earnings guidance as Humira sales top estimates…

AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups 24 EPS View

AbbVies (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.…

AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?

The big pharma companys top drug is losing ground, but its dividend keeps rising.…

AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now? @themotleyfool #stocks $ABBV $AZN $CVS $UNH $ABT $BGNE $CI $RVNC

The big pharma companys top drug is losing ground, but its dividend keeps rising.…

dpa-AFX ProFeed